EL PASO, Texas, Apr 02, 2014 (BUSINESS WIRE) — Premier Biomedical, Inc. (OTCBB:BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has prepared and will file a provisional patent application for an anti-breast cancer treatment methodology protocol, in conjunction with its partners in R&D at the Department of Defense (DOD) with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) covering its study accepted for presentation at the American Association for Cancer Research (AACR) annual convention April 7-8, 2014 in San Diego. In addition, the group has discovered and will initiate an accelerated development program on two additional anti-cancer drug methodology protocols that it believes are unique in the industry and very promising.
Premier Biomedical’s President and CEO, William A. Hartman, stated, “We are extremely excited about our accomplishments to date in the area of developing an effective anti-breast cancer treatment, as stated in our peer-reviewed study accepted by the AACR, but even more excited about the potential discovery of two new, unique anti-cancer treatment regimens and the possibility that they may be effective against a range of cancer types. We understand that a lot of research has to be accomplished on these new treatments, but we have developed the planned test procedures and have approved funding to proceed at full speed. Because of our R&D relationships with the DOD and UTEP, we have the organizational flexibility to respond quickly and seamlessly to increased workload and new projects with highly experienced and qualified personnel.”
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and US Department of Defense, specifically targeting the treatment of Alzheimer’s disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig’s Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with business offices in Pennsylvania. The Company’s common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol “BIEI.” www.premierbiomedicalinc.com
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.